Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.

Tang H, Yan Y, Feng Z, de Jesus RK, Yang L, Levorse DA, Owens KA, Akiyama TE, Bergeron R, Castriota GA, Doebber TW, Ellsworth KP, Lassman ME, Li C, Wu MS, Zhang BB, Chapman KT, Mills SG, Berger JP, Pasternak A.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6088-92. doi: 10.1016/j.bmcl.2010.08.047. Epub 2010 Aug 20.

PMID:
20832306
2.

Ginseng berry reduces blood glucose and body weight in db/db mice.

Xie JT, Zhou YP, Dey L, Attele AS, Wu JA, Gu M, Polonsky KS, Yuan CS.

Phytomedicine. 2002 Apr;9(3):254-8.

PMID:
12046868
3.

Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents.

Tassoni E, Giannessi F, Brunetti T, Pessotto P, Renzulli M, Travagli M, Rajamäki S, Prati S, Dottori S, Corelli F, Cabri W, Carminati P, Botta M.

J Med Chem. 2008 Jun 12;51(11):3073-6. doi: 10.1021/jm8001636. Epub 2008 May 9.

PMID:
18465847
4.

Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes.

Xu Q, Huang L, Liu J, Ma L, Chen T, Chen J, Peng F, Cao D, Yang Z, Qiu N, Qiu J, Wang G, Liang X, Peng A, Xiang M, Wei Y, Chen L.

Eur J Med Chem. 2012 Jun;52:70-81. doi: 10.1016/j.ejmech.2012.03.006. Epub 2012 Mar 13.

PMID:
22483089
5.

Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.

Ha TY, Kim YS, Kim CH, Choi HS, Yang J, Park SH, Kim DH, Rhee JK.

Arch Pharm Res. 2014 May;37(5):671-8. doi: 10.1007/s12272-013-0209-0. Epub 2013 Jul 30.

PMID:
23897163
6.

Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.

Li Z, Qiu Q, Xu X, Wang X, Jiao L, Su X, Pan M, Huang W, Qian H.

Eur J Med Chem. 2016 May 4;113:246-57. doi: 10.1016/j.ejmech.2016.02.040. Epub 2016 Feb 21.

PMID:
26945112
7.

Novel thiazolidine-2,4-diones as potent euglycemic agents.

Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, Lamphere CH, Lewis DM, Rizzi JP.

J Med Chem. 1992 May 15;35(10):1853-64.

PMID:
1588563
8.

Antidiabetic and antiobesity effects of Ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase.

Oh S, Kim SJ, Hwang JH, Lee HY, Ryu MJ, Park J, Kim SJ, Jo YS, Kim YK, Lee CH, Kweon KR, Shong M, Park SB.

J Med Chem. 2010 Oct 28;53(20):7405-13. doi: 10.1021/jm100565d.

PMID:
20873794
9.

Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.

[No authors listed]

Cardiovasc J Afr. 2008 Sep-Oct;19(5):282-3. No abstract available.

10.

Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.

Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong G, Singh R, Shapses S, Malm J, Webb P, Baxter JD, Grover GJ.

J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):262-7. doi: 10.1016/j.jsbmb.2008.06.010. Epub 2008 Jun 22.

PMID:
18621127
11.

Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity.

Pei Z, Liu G, Lubben TH, Szczepankiewicz BG.

Curr Pharm Des. 2004;10(28):3481-504. Review.

PMID:
15579047
12.

Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors.

Wallace DM, Haramura M, Cheng JF, Arrhenius T, Nadzan AM.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):1127-30. Epub 2007 Jan 17.

PMID:
17234415
13.

X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and reduces hyperglycemia and obesity in db/db mice.

Han J, Yi J, Liang F, Jiang B, Xiao Y, Gao S, Yang N, Hu H, Xie WF, Chen W.

Mol Cell Endocrinol. 2015 Apr 15;405:63-73. doi: 10.1016/j.mce.2015.02.008. Epub 2015 Feb 11.

PMID:
25681564
14.

Treating the obese diabetic.

Kenkre J, Tan T, Bloom S.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):171-83. doi: 10.1586/ecp.13.5. Review.

PMID:
23473594
15.

Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis.

Yoshida T, Umekawa T, Wakabayashi Y, Yoshimoto K, Sakane N, Kondo M.

Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):476-82.

PMID:
8800569
16.

Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.

Reddy KA, Lohray BB, Bhushan V, Reddy AS, Kishore PH, Rao VV, Saibaba V, Bajji AC, Rajesh BM, Reddy KV, Chakrabarti R, Rajagopalan R.

Bioorg Med Chem Lett. 1998 May 5;8(9):999-1002. Erratum in: Bioorg Med Chem Lett 1998 Aug 4;8(15):2059.

PMID:
9871696
17.

[Effects of Panax notoginseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice].

Yang CY, Xie ZG, Cheng WB, Jiang X, Chen ZH.

Zhong Yao Cai. 2009 Oct;32(10):1571-6. Chinese.

PMID:
20112724
18.

Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.

Chen H, Dardik B, Qiu L, Ren X, Caplan SL, Burkey B, Boettcher BR, Gromada J.

Endocrinology. 2010 Jul;151(7):3115-24. doi: 10.1210/en.2009-1366. Epub 2010 May 19.

PMID:
20484464
19.

Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.

Li CS, Belair L, Guay J, Murgasva R, Sturkenboom W, Ramtohul YK, Zhang L, Huang Z.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5214-7. doi: 10.1016/j.bmcl.2009.07.015. Epub 2009 Jul 9.

PMID:
19632834
20.

Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.

Aicher TD, Balkan B, Bell PA, Brand LJ, Cheon SH, Deems RO, Fell JB, Fillers WS, Fraser JD, Gao J, Knorr DC, Kahle GG, Leone CL, Nadelson J, Simpson R, Smith HC.

J Med Chem. 1998 Nov 5;41(23):4556-66.

PMID:
9804695

Supplemental Content

Support Center